Effects of antiobesity agents on liver function tests and plasma creatine kinase values in male rats
A significant decrease in creatine kinase levels was observed only after the administration of DOV 21947 (6 mg/kg b.i.d. p.o.). None of the other treatments caused significant changes in the measured parameters.
Treatment | Alkaline Phosphatase | Alanine Aminotransferase | Aspartate Aminotransferase | Lactate Dehydrogenase | Albumen | Globulin | Albumen/Globulin | Total Bilirubin | Creatine Kinase | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| U / l | g / l | mg / dl | U / l | ||||||||
| Vehicle | 105 ± 6 | 37 ± 4 | 116 ± 14 | 499 ± 115 | 4.4 ± 0.1 | 2.6 ± 0.1 | 1.7 ± 0.0 | 0.5 ± 0.1 | 364 ± 78 | ||
| DOV 21947 | 111 ± 11 | 45 ± 5 | 115 ± 22 | 574 ± 191 | 4.6 ± 0.1 | 2.8 ± 0.1 | 1.7 ± 0.1 | 0.5 ± 0.1 | 249 ± 48 | ||
| 6 mg/kg | |||||||||||
| 6 mg/kg b.i.d. | 100 ± 7 | 38 ± 3 | 83 ± 7 | 295 ± 44 | 4.6 ± 0.1 | 2.5 ± 0.1 | 1.9 ± 0.1 | 0.5 ± 0.1 | 133 ± 23* | ||
| 20 mg/kg | 89 ± 3 | 38 ± 3 | 94 ± 15 | 436 ± 84 | 4.6 ± 0.1 | 2.6 ± 0.1 | 1.8 ± 0.0 | 0.4 ± 0.1 | 245 ± 73 | ||
| AM251, 3 mg/kg | 89 ± 4 | 34 ± 4 | 93 ± 6 | 288 ± 56 | 4.6 ± 0.1 | 2.7 ± 0.1 | 1.7 ± 0.1 | 0.3 ± 0.0 | 197 ± 31 | ||
| d-Fenfluramine, 3 mg/kg | 87 ± 7 | 30 ± 4 | 81 ± 11 | 346 ± 76 | 4.5 ± 0.1 | 2.9 ± 0.1 | 1.6 ± 0.1 | 0.4 ± 0.1 | 192 ± 48 | ||
| Sibutramine, 2 mg/kg | 89 ± 3 | 30 ± 3 | 87 ± 12 | 225 ± 25 | 4.4 ± 0.1 | 2.6 ± 0.1 | 1.7 ± 0.0 | 0.3 ± 0.0 | 198 ± 57 | ||
↵* P < 0.05, significantly different from vehicle levels, one-way ANOVA and Dunnett's post hoc test [F(7,47) = 1.333; P = 0.26].